目的 探討疏血通注射液聯(lián)合納洛酮治療慢性肺心病急性加重期對(duì)血漿內(nèi)皮素（ET-1）的影響。方法 采用回顧性與便利抽樣研究方法，病例收治時(shí)間為2010年2月—2016年12月，選擇在此期間在西安市五環(huán)集團(tuán)職工醫(yī)院診治的慢性肺心病急性加重期患者122例，按照治療方法的區(qū)別分為觀察組與對(duì)照組各61例，對(duì)照組給予納洛酮治療，2 mg加入0.9% NaCl注射液100 mL中靜滴，1次/d。觀察組在對(duì)照組治療的基礎(chǔ)上給予疏血通注射6 mL加入0.9% NaCl注射液100 mL中靜滴，1次/d。兩組都治療觀察28 d。比較兩組療效、三尖瓣區(qū)最大返流速度（V_max）和肺動(dòng)脈壓（PAPs）及ET-1水平，同時(shí)比較兩組凝血功能指標(biāo)。結(jié)果 對(duì)照組總有效率為86.9%，觀察組為98.4%，觀察組顯著高于對(duì)照組（P<0.05）。治療后兩組的V_max值、PAPs值與血漿ET-1含量均顯著低于治療前（P<0.05），且觀察組顯著低于對(duì)照組（P<0.05）。治療后兩組的凝血酶原時(shí)間（PT）、活化部分凝血活酶時(shí)間（APTT）與凝血酶時(shí)間（TT）值都顯著高于治療前（P<0.05），且治療后觀察組顯著高于對(duì)照組（P<0.05）。結(jié)論 疏血通注射液聯(lián)合納洛酮治療慢性肺心病急性加重期能抑制血漿ET-1的表達(dá)，改善肺動(dòng)脈壓力，具有抗凝的作用，從而有利于提高治療療效。

Objective To investigate the effect of Shuxuetong Injection on plasma endothelin (ET-1) in acute exacerbation of chronic pulmonary heart disease.Methods Used a random draw and retrospective study, From February 2010 to December 2016, 122 cases of acute exacerbation of chronic pulmonary heart disease in our hospital were selected and were ivided into observation group and control group with 61 cases in each group accorded to the different treatment methods, the control group was received naloxone treatment, the observation group was given Shuxuetong Injection therapy based on the control group treatment, all the cases were given reated 28 d.Results The total effective rate of the observation group and the control group was 98.4% and 86.9% respectively, and the observation group was significantly higher than that of the control group (P<0.05). After treatment, the value of V_max and PAPs in the two groups were significantly lower than that before treatment (P<0.05), and the value of V_max and PAPs in the observation group after treatment were significantly lower than that of the control group (P<0.05). The plasma ET-1 content in the observation group and the control group after treatment were significantly lower than that before the treatment (P<0.05), and the observation group were also significantly lower than that of the control group (P<0.05). After treatment, the values of PT, APTT and TT were higher than those before treatment (P<0.05), and the values of PT, APTT and TT in the observation group were also higher than those of the control group after the treatment (P<0.05).Conclusion The Shuxuetong injection can inhibit the expression of plasma ET-1 and improve the pulmonary artery pressure in patients with acute exacerbation of chronic pulmonary heart disease, and it has anticoagulant effect, which is beneficial to improve the therapeutic effect.